FDA monthly preview: Key October decisions to watch
Several FDA decisions across multiple specialties are expected this month.
By
Kathryn Wighton
September 25, 2026
Clinical Scorecard: FDA monthly preview: Key October decisions to watch
At a Glance
Category Detail
Condition Various conditions including renal cell carcinoma, colon cancer, small cell lung cancer, thyroid eye disease, presbyopia, chronic hepatitis B, psoriatic arthritis, and recurrent respiratory papillomatosis Key Mechanisms Therapies include biologics and investigational drugs targeting specific pathways and conditions Target Population Adults with specified conditions Care Setting Oncology, ophthalmology, gastroenterology, rheumatology, otolaryngology, endocrinology, infectious disease
Key Highlights
Atezolizumab shows 50% reduced risk of recurrence in stage III colon cancer Ifinatamab deruxtecan targets extensive-stage small cell lung cancer Satralizumab demonstrates significant proptosis response in thyroid eye disease Bepirovirsen achieves higher functional cure rates in chronic hepatitis B INO-3107 reduces surgeries in recurrent respiratory papillomatosis Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults with specific conditions under review
Investigational therapies showing promise in clinical trials
Clinical Best Practices
Related Resources & Content
